Skip to main content
SpringerLink
Log in

Medikamentöses Therapieschema bei Patienten mit schizophrener Minussymptomatik

  • Chapter
Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik

  • 17 Accesses

Zusammenfassung

Konzeptionelle und diagnostische Fragestellungen im Zusammenhang mit der schizophrenen Minussymptomatik werden seit der von Crow (1980) vorgeschlagenen Typisierung der Schizophrenien in einen Typ-1 und Typ-2 intensiv diskutiert, wobei eine verbindliche Einteilung bisher jedoch noch nicht vorliegt. Nach der anfänglichen Fokussierung auf Diagnostik und Pathogenese der schizophrenen Minussymptomatik traten in den vergangenen Jahren pharmakotherapeutische Aspekte zur Beeinflussung von Minussymptomen bei schizophren Erkrankten in den Vordergrund wissenschaftlichen Interesses. Ein allgemeingültiges Therapiekonzept zur Behandlung der Minussymptomatik bei schizophrenen Patienten gibt es derzeit jedoch noch nicht, da

  1. 1.

    schizophrene Minussymptome multifaktoriell bedingt sind,

  2. 2.

    geeignete Tiermodelle für die Negativsymptomatik nicht zur Verfügung stehen und

  3. 3.

    die meisten der bislang durchgeführten Therapiestudien erhebliche methodische Mängel aufweisen:

    so war das Studiendesign der bisher publizierten Studien meist so konzipiert, daß primär das Ansprechen akuter produktiver Symptomatik auf Neuroleptika und erst sekundär das Ansprechen der Minussymptomatik geprüft wurde. Ein weiteres methodisches Problem der vorliegenden Studien, das die Erstellung therapeutischer Richtlinien erheblich erschwert, stellen der geringe Stichprobenumfang und der häufig kurze, nur wenige Wochen betragende, Untersuchungszeitraum dar.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alphs L, Lafferman J, Ross L, Bland W, Levine J (1989) Fenfluramine treatment of negative symptoms in older schizophrenic inpatients. Psychopharmacol Bull 25: 149–153

    PubMed  CAS  Google Scholar 

  • Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784–788

    Article  PubMed  CAS  Google Scholar 

  • Angrist B, Peselow E, Rubinstein M, et al (1982) Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology 78: 128–130

    Article  PubMed  CAS  Google Scholar 

  • Angst J, Stassen H, Woggon B (1989) Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacology 99: 41–46

    Article  Google Scholar 

  • Bleuler E (1911) Dementia praecox oder die Gruppe der Schizophrenien. In: Aschaffenburg G (Hrsg) Handbuch der Psychiatrie, 4. Abteilung, 1. Hälfte. Deuticke, Leipzig

    Google Scholar 

  • Breier A, Wolkowitz O, Doran A, Roy A, Boronow J, Hommer D, Dickar D (1987) Neuroleptic responsitivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144: 1549–1555

    PubMed  CAS  Google Scholar 

  • Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91: 104–108

    Article  PubMed  CAS  Google Scholar 

  • Carnoy P, Soubrie P, Puech A, Simon P (1986) Performance deficit induced by low doses of dopamine agonists in rats. Biol Psychiatry 21: 11–22

    Article  PubMed  CAS  Google Scholar 

  • Carpenter W, Heinrichs D, Alphs L (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452

    PubMed  Google Scholar 

  • Cesarec Z, Nyman A (1985) Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 71: 523–538

    Article  PubMed  CAS  Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1992) A canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40

    Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66–68

    Article  PubMed  CAS  Google Scholar 

  • Csernansky J, Riney S, Lombrozo L, Overall J, Hollister L (1988) Double-blind comparison of alprazolam, diazepam and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry 45: 655–659

    Article  PubMed  CAS  Google Scholar 

  • Davis K. L, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474–1486

    PubMed  CAS  Google Scholar 

  • Eccleston D, Fairbairn A, Hassanyeh F, McClelland H, Stephens D (1985) The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiatry 147: 623–630

    Article  PubMed  CAS  Google Scholar 

  • Fisch R (1987) Trihexyphenidylabuse: therapeutic implications for negative symptoms of schizophrenia. Acta Psychiatr Scand 75: 91–94

    Article  PubMed  CAS  Google Scholar 

  • Fleischhacker W, Barnas C, Stuppäck C, Unterweger B, Hinterhuber H (1987) Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 20: 58–60

    Article  PubMed  CAS  Google Scholar 

  • Frangos H, Zissis N, Leontopoulos J, Diamantas W, Tsituouridis S, Gavrill I, Tsolis K (1978) Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatr Scand 57: 436–446

    Article  PubMed  CAS  Google Scholar 

  • Gerlach J, Lühdorf K (1975) The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. Psychopharmacologia 44: 105–110

    Article  PubMed  CAS  Google Scholar 

  • Gerlach J (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17: 289–309

    PubMed  CAS  Google Scholar 

  • Goff D, Brotman A, Waites M, McCormick S (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 147: 492–494

    PubMed  CAS  Google Scholar 

  • Goldberg S (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456

    PubMed  CAS  Google Scholar 

  • Haas S, Beckmann H (1982) Pimozide versus haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatry 15: 70–74

    Article  CAS  Google Scholar 

  • Herith AJ (1992) The dopamine hypothesis and neurophysiologie concepts in schizophrenia. Rev Neurosci 3: 207–216

    Article  Google Scholar 

  • Janssen P, Niemegeers C, Awouters F, Schellekens K, Megens A, Meert T (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693

    PubMed  CAS  Google Scholar 

  • Johnstone EC, Frith CD, Crow TJ, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 18: 848–851

    Article  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796

    Article  PubMed  CAS  Google Scholar 

  • Kane J (1989) The current status of neuroleptic therapy. J Clin Psychiatry 50: 322–328

    PubMed  CAS  Google Scholar 

  • Kane J, Mayerhoff D (1989) Do negative symptoms respond to pharmacological treatment. Br J Psychiatry 155 [Suppl 7]: 115–118

    Google Scholar 

  • Kornhuber J, Beckmann H, Riederer P (1990) Das dopaminerg-glutamaterge Gleichgewicht unter dem Aspekt von schizophrener Plus-and Minussymptomatik. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik and Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 119–126

    Chapter  Google Scholar 

  • Kraepelin E (1913) Psychiatrie. Ein Lehrbuch für Studierende and Ärzte, 8. Aufl. Barth, Leipzig

    Google Scholar 

  • Kulhara P, Avashti A, Chedda R, Chandiramani K, Mattoo SK, Kota SK, Joseph S (1989) Negative and depressive symptoms in schizophrenia. Br J Psychiatry 154: 207–211

    Article  PubMed  CAS  Google Scholar 

  • Lapierre Y, Lavallee J (1975) Pimozide and the social behavior of schizophrenics. Curr Ther Res 18: 181–188

    PubMed  CAS  Google Scholar 

  • Levi-Minzi S, Bermanzohn PC, Siris SG (1991) Bromocriptine for „negative“ schizophrenia. Compr Psychiatry 32: 210–216

    Article  PubMed  CAS  Google Scholar 

  • Lewander T, Westerbergh SE, Morrison D (1990) Clinical profile of remoxipride combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand 82 [Suppl 358]: 92–98

    Article  Google Scholar 

  • Leysen JE, Gommeren W, Eens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ (1988) The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661–670

    PubMed  CAS  Google Scholar 

  • Markstein R (1993) Bedeutung neuer Dopaminrezeptoren für die Wirkung von Clozapin. In: Naher D, Müller-Spahn F (Hrsg) Clozapin, Pharmakologie und Klinik eines atypischen Neuroleptikums. Neue Aspekte in der klinischen Praxis. Springer, Berlin Heidelberg New York Tokyo, S 5–15

    Google Scholar 

  • Meltzer HY, Zureick J (1989) Negative symptoms in schizophrenia: a target for new drug development. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 68–77

    Google Scholar 

  • Meltzer H (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287

    PubMed  CAS  Google Scholar 

  • Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H, Yamada M (1991) Effects of mianserin on negative symptoms in schizophrenia. Int Clin Psychopharmacol 5: 83–95

    Article  Google Scholar 

  • Müller-Spahn F (1990) Die Bedeutung von Neuroleptika der neueren Generation: Perspektiven in der Therapie schizophrener Patienten mit Minussymptomatik. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 207–216

    Chapter  Google Scholar 

  • Müller-Spahn F, Botschev C, Dieterle D (1990) Efficacy and tolerability of risperidone, a serotonine S2 and dopamine D2 receptor antagonist, in the treatment of chronic schizophrenic patients. 17 Congress of CINP, Kyoto

    Google Scholar 

  • Müller-Spahn F, Dieterle D, Ackenheil M (1991) Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik. Fortschr Neurol Psychiat 59: 30–35

    Article  PubMed  Google Scholar 

  • Müller-Spahn F, Modell S, Thomma M (1992) Neue Aspekte in der Diagnostik, Pathogenese und Therapie schizophrener Minussymptomatik. Nervenarzt 63: 383–400

    PubMed  Google Scholar 

  • Mundt C, Kasper S (1987) Zur Schizophreniespezifität von negativen und Basissymptomen. Nervenarzt 58: 489–495

    PubMed  CAS  Google Scholar 

  • Naber D, Gaussares C, Moeglen JM, Tremmel L, Bailey PE (1992a) Efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 99–107

    Google Scholar 

  • Naher D, Holzbach R, Perro C, Hippius H (1992b) Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 160 [Suppl 17]: 54–59

    Google Scholar 

  • Nestadt G, McHugh P (1985) The frequency and specifity of some negative symptoms. In: Huber G (Hrsg) Basisstadien endogener Psychosen und das Borderlineproblem. Schattauer, Stuttgart

    Google Scholar 

  • Ogren SO, Florvall L, Hall H, Magnusson O, Ängeby-Möller K (1990) Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 82 [Suppl 358]: 21–26

    Article  Google Scholar 

  • Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenia. Pharmacopsychiatry 21: 389–390

    Article  PubMed  CAS  Google Scholar 

  • Reyntjens A, Golders Y, Hoppenbrouwers M, van den Bussche G (1986) Thymostenic effects of ritanserin (R 55667), a centrally acting serotonin S-2-receptor blocker. Drug Dev Res 8: 205–211

    Article  CAS  Google Scholar 

  • Seeman P (1992) Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D-2 receptors, clozapine occupies D-4. Neuropsychopharmacology 7: 261–284

    PubMed  CAS  Google Scholar 

  • Serban G, Seymour S, Gaffney M (1992) Response of negative symptoms of schizophrenia to neuroleptic treatment. J Clin Psychiatry 53: 229–234

    PubMed  CAS  Google Scholar 

  • Shimomura K, Saton H, Hivai O, Mori J, Tomoi T, Terai T, Katsuki S, Motoyama Y, Ono T (1982) The central anti-serotonin activity of zotepine, a new neuroleptic in rats. Jpn Pharmacol 32: 405–412

    Article  CAS  Google Scholar 

  • Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31: 698–704

    Article  PubMed  CAS  Google Scholar 

  • Siris S, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988) Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 145: 1532–1537

    PubMed  CAS  Google Scholar 

  • Siris S, Mason S, Bermanzohn P, Alvir M, McCorry T (1990) Adjunctive imipramine maintenance in postpsychotic depression/negative symptoms. Psychopharmacol Bull 26: 91–94

    PubMed  CAS  Google Scholar 

  • Tandon R, Greden J, Silk K (1988) Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 8: 212–215

    Article  PubMed  CAS  Google Scholar 

  • Tandon R, Greden J (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. Arch Gen Psychiatry 46: 745–752

    Article  PubMed  CAS  Google Scholar 

  • Tandon R, Mann N, Eisner W, Coppard N (1990) Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatr Res 31: 235–241

    Article  CAS  Google Scholar 

  • Tandon R, Shipley J, Greden J, Mann N, Eisner W, Goodson J (1991) Muscarinic cholinergic hyperactivity in schizophrenia. Schizophr Res 4: 23–30

    Article  PubMed  CAS  Google Scholar 

  • Tegeler J (1990) Empirische Befunde zum Einsatz von Antidepressiva zur Therapie von Minussymptomen. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 241–252

    Chapter  Google Scholar 

  • Uchida S, Honda F, Otsuka M, Satoh Y, Mori J, Ono T, Hitomie M (1979) Pharmacological study of (2-chloro-11- (2-dimethylamino-ethoxy) dibenzo (b, f) thiepine) (zotepine), a new neuroleptic drug. Arzneimittelforschung/Drug Res 29: 1588–1594

    CAS  Google Scholar 

  • Uhr S, Jackson K, Berger P, Csernansky J (1988) Effects of verapamil administration on negative symptoms of chronic schizophrenia. Psychiatry Res 23: 351–352

    Article  PubMed  CAS  Google Scholar 

  • Van Kammen D, Peters J, Yao J, van Kammen W, Neylan T, Shaw D, Linnoila M (1990) Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry 47: 161–168

    Article  PubMed  Google Scholar 

  • Wachtel H, Dorow R (1983) Dual action, a central dopamine function of transhydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci 32: 421–432

    Article  PubMed  CAS  Google Scholar 

  • Waddington J, Yousseff H, Dolphin C, Kinsella A (1987) Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 44: 907–912

    Article  PubMed  CAS  Google Scholar 

  • Weinberger DR, Bigelow LB, Kleinman JE (1980) Cerebral ventricular enlargement and poor response to treatment. Arch Gen Psychiatry 37: 11–13

    Article  PubMed  CAS  Google Scholar 

  • Wetzel H, Hillert A, Gründer G (1990) Behandlung der schizophrenen Negativ-Symptomatik mit Dopamin-Autorezeptor-Agonisten: Erste Erfahrungen mit Roxindol. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 231–239

    Chapter  Google Scholar 

  • Wiedemann K, Benkert O, Holsboer F (1990) B-HT 920 — a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–55

    Article  PubMed  CAS  Google Scholar 

  • Wiesel F, Alfredsson G, Bjerkenstedt L, Härnryd C, Oxenstierna G, Sedvall G (1985) Dogmatil in der Behandlung der Minussymptomatik bei schizophrenen Patienten. Semin Hop Paris 61: 1317–1321

    Google Scholar 

  • Wilson L, Roberts R, Gerber C (1982) Pimozide vs chlorpromazine in chronic schizophrenia: a 52 week double-blind study of maintenance therapy. J Clin Psychiatry 43: 62–65

    PubMed  CAS  Google Scholar 

  • Wing J, Brown G (1961) Social treatment of chronic schizophrenia: a comparative survey of three mental hospitals. J Ment Sci 107: 847–861

    Google Scholar 

  • Wing J (1989) The concept of negative symptoms. Br J Psychiatry 155 [Suppl 7]: 10–14

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Klinik und Poliklinik, LM-Universität München, Bundesrepublik Deutschland

    Prof. Dr. F. Müller-Spahn & G. Kurtz

Authors
  1. Prof. Dr. F. Müller-Spahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Kurtz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik und Poliklinik, Sigmund-Freud-Straße 25, D-53105, Bonn, Deutschland

    Hans-Jürgen Möller  & Gerd Laux  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag/Wien

About this chapter

Cite this chapter

Müller-Spahn, F., Kurtz, G. (1994). Medikamentöses Therapieschema bei Patienten mit schizophrener Minussymptomatik. In: Möller, HJ., Laux, G. (eds) Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9349-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9349-5_22

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82547-1

  • Online ISBN: 978-3-7091-9349-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation